Season 2 (2021-2030)

Ophthalmology - Phase1 (1)

Modality Indication Targets Stage Company Project No. Detail
1 Phase 1 clinical study of first in class tie2 activator PMC.403 in patients with age.related macular degeneration
Antibody Macular degeneration TIE.2 Phase 1 Pharm Abcine Inc. RS-2023-00282791
BACK